What is Prota Therapeutics?
Prota Therapeutics is a late clinical-stage biotechnology firm dedicated to developing innovative oral immunotherapies for food allergies. The company's primary focus is on addressing peanut allergies, a widespread and serious health concern. Their lead candidate, PRT120, is poised for Phase 3 trials and is built upon extensive research conducted over two decades by Professor Mimi Tang at the Murdoch Childrens Research Institute. Prota's investigational treatments aim to substantially improve the quality of life for individuals affected by food allergies, offering a potential new avenue for management beyond current avoidance strategies.
How much funding has Prota Therapeutics raised?
Prota Therapeutics has raised a total of $21M across 1 funding round:
Other Financing Round
$21M
Other Financing Round (2024): $21M, investors not publicly disclosed
What's next for Prota Therapeutics?
With a major strategic investment bolstering its development pipeline, Prota Therapeutics is well-positioned to advance its lead candidate, PRT120, into Phase 3 clinical trials. This enterprise-level funding suggests strong confidence from investors in the company's therapeutic approach and its potential to address the significant unmet need in food allergy treatment. The company's next steps will likely involve executing its late-stage clinical strategy, navigating regulatory pathways, and preparing for potential commercialization, aiming to bring its novel allergen immunotherapy to market.
See full Prota Therapeutics company page
